Tissue factor pathway inhibitor (TFPI) in patients with occlusive arterial diseases in consideration with risk factors and conservative treatment of the disease

Abstract

The aim of the study was to determine the level of tissue factor pathway inhibitor (TFPI) in patients with arterial occlusive diseases of the lower limbs and to consider correlation of TFPI with some risk factors of the development of these diseases: cigarette smoking, hyperlipidaemia and age. The effect of conservative treatment with pentoxifylline and alprostadil of the peripheral arterial occlusive disease (PAOD) on plasma concentration of TFPI was also investigated. TFPI concentration was not dependent on the age of healthy per sons. Patients with PAOD or Buerger`s disease showed elevated concentrations of TFPI compared to healthy adults without any symptoms of the arterial disease, 333.3 ± 100.2 ng/mL, 177.9 ± 67.1 ng/mL, 95.7 ± ± 25.3 ng/mL respectively. There are no significant differences of TFPI concentration in smokers, former smokers and non-smokers in the group of healthy persons. Conservative treatment of PAOD with pentoxifylline or alprostadil had no effect on TFPI concentration in patients with PAOD. The results of the study suggest, that the elevated TFPI concentration in patients with arterial occlusive diseases mainly depends on state of the vascular endothelium.